Articles producció científica> Química Analítica i Química Orgànica

Silicon particles as trojan horses for potential cancer therapy

  • Identification data

    Identifier: PC:1009
    Handle: https://hdl.handle.net/20.500.11797/PC1009
    Authors:
    Fenollosa, R.Garcia-Rico, E.Alvarez, S.Alvarez, R.Yu, X.Rodriguez, I.Carregal-Romero, S.Villanueva, C.Garcia-Algar, M.Rivera-Gil, P.de Lera A.R.Parak, W.J.Meseguer, F.Alvarez-Puebla, R.A.
    Abstract:
    10.1186/s12951-014-0035-7

  • Others:

    Author, as appears in the article.: Fenollosa, R. Garcia-Rico, E. Alvarez, S. Alvarez, R. Yu, X. Rodriguez, I. Carregal-Romero, S. Villanueva, C. Garcia-Algar, M. Rivera-Gil, P. de Lera A.R. Parak, W.J. Meseguer, F. Alvarez-Puebla, R.A.
    Department: Química Analítica i Química Orgànica
    URV's Author/s: Roberto Fenollos, Eduardo Garcia-Rico, Susana Alvarez, Rosana Alvarez, Xiang Yu, Isabel Rodriguez , Susana Carregal-Romero, Carlos Villanueva, Manuel Garcia-Algar, Pilar Rivera-Gil, Angel R de Lera, Wolfgang J Parak, Francisco Meseguer, Ramón A Alvarez-Puebla,
    Abstract: Background: Porous silicon particles (PSiPs) have been used extensively as drug delivery systems, loaded with chemical species for disease treatment. It is well known from silicon producers that silicon is characterized by a low reduction potential, which in the case of PSiPs promotes explosive oxidation reactions with energy yields exceeding that of trinitrotoluene (TNT). The functionalization of the silica layer with sugars prevents its solubilization, while further functionalization with an appropriate antibody enables increased bioaccumulation inside selected cells. Results: We present here an immunotherapy approach for potential cancer treatment. Our platform comprises the use of engineered silicon particles conjugated with a selective antibody. The conceptual advantage of our system is that after reaction, the particles are degraded into soluble and excretable biocomponents. Conclusions: In our study, we demonstrate in particular, specific targeting and destruction of cancer cells in vitro. The fact that the LD50 value of PSiPs-HER-2 for tumor cells was 15-fold lower than the LD50 value for control cells demonstrates very high in vitro specificity. This is the first important step on a long road towards the design and development of novel chemotherapeutic agents against cancer in general, and breast cancer in particular.
    licence for use: https://creativecommons.org/licenses/by/3.0/es/
    Keyword in other language: Cancer therapy Silicon particles Trojan horse
    ISSN: 1477-3155
    Last page: 10
    Journal volume: 12
    Papper version: info:eu-repo/semantics/publishedVersion
    Licence document URL: https://repositori.urv.cat/ca/proteccio-de-dades/
    Entity: Universitat Rovira i Virgili.
    Journal publication year: 2014
    First page: 1